Radiopharm completes FDA end-of-Phase 2 meeting for RAD101 ahead of pivotal brain metastases imaging trial

By Public Technologies
  • Radiopharm Theranostics completed an FDA end-of-Phase 2 meeting for RAD101, setting the framework for a pivotal brain-metastases imaging program.
  • Phase 2b results were previously presented, supporting continued development based on performance versus standard imaging assessments.
  • The update shifts focus to Phase 3 readiness work ahead of FDA meeting minutes expected within about 30 days.
  • RAD101 holds FDA Fast Track status, strengthening its regulatory positioning for a registrational study.
  • Siemens Healthineers will manufacture and distribute RAD101 doses for the planned U.S. Phase 3 trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED1001276171) on October 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.